Menu

Fuchs on the Future

Rockefeller University researcher Elaine Fuchs on being a woman in science and her contributions to the burgeoning field of reverse genetics

May 1, 2016
The Scientist Staff
Elaine Fuchs pioneered the field of reverse genetics—studying proteins and learning what they do, and how they do it, in order to identify the genetic disease they cause when they malfunction.
Narrator: How do you go forward in reverse? Ask Elaine Fuchs. She created a field called reverse genetics that revolutionized the study of genetic disease. Elaine Fuchs: At the time, researchers would identify a large family that had a inheritable trait that was passaged on to their offspring. Narrator: Geneticists would study the DNA of unhealthy family members, compare that to the DNA of healthy family members, and try to find differences that may or may not have been the source of the disease. Elaine Fuchs: So, they would use that information to then do what I consider quite boring science at the time. And that was to slog through megabases of DNA and try to find a needle in the haystack. I thought, ‘Wouldn't it be nice if you could just start with the protein?’ Narrator: Proteins are critical molecules in our cells. And each protein has a different job, like cellular structural support and defense against germs. Fuchs began to disrupt the proteins in skin cells and then implant those mutated proteins in mice to see what skin abnormalities might development. Elaine Fuchs: That's what we call reverse genetics, starting with the protein and working your way up to a genetic disease rather than starting with the disease and working your way down to the protein. We engineered a mouse to express our mutant protein and let the mouse pathology guide us to what disease the human must have. So, when I first presented this work at a scientific meeting, the chairman took the microphone and said, "I don't know what disease you've got, but it's certainly not the one that you think it is. And this to me just seems like really ridiculous science. I think we should move on." And the audience was silent. Nobody spoke up. One woman finally stood up in the audience and said, "I think you should give this woman a chance." And it was six months later that we proved we had been right in our diagnosis. Narrator: Fuchs not only solved what caused the skin disease, she forever changed genetic science, an impressive achievement for a small-town girl. Elaine Fuchs: I was born in Downers Grove, Illinois, just southwest of Chicago. My aunt and my fathe

Read the full story.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.